Alternatively, we reported here that targeting the downstream core cancer drivers (CDRs) of RB1/E2F1, either through gene silencing using specific CRISPR-Cas13 (Fig. 4I–L) or with small molecular inhibitors (Fig. 7A–G), may achieve anti-tumor goals. This evidence concerns the gene E2F1 and neoplasm.